Ganciclovir

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Ganciclovir
   1. Pharmacist Assessment Report
   2. Ganciclovir: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Cytotoxicity
   8. Safety Considerations
   9. Disclaimer

---

Pharmacist Assessment Report

Ganciclovir: Known uses and market status in Australia

Summary

The TxGNN model (deep learning) has no candidate with a score of 0.99 or higher for this drug, so there is currently no new predicted indication on this page. The diseases listed below are known uses or were removed from the prediction list. They are not predictions.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	3
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
cytomegalovirus retinitis
herpes simplex virus keratitis
ventricular tachycardia

Australia Market Information

Licence	Product	Dosage form	Status
10328N	Cymevene	Powder for I.V. infusion 500 mg (as sodi	Valid

Cytotoxicity

Ganciclovir is an antiviral, not a conventional anticancer drug, but it is a nucleoside analogue with significant haematological toxicity. The data compiled for this report did not include a formal cytotoxicity classification, so please refer to the Product Information (PI) warnings and precautions, including requirements for handling and disposal.

Safety Considerations

• Knowledge-graph contraindication signals (these come from a knowledge graph, not from label text, and should be checked against the PI): thrombocytopenia, neutropenia, agranulocytosis, anaemia, cyclic haematopoiesis, kidney disease, and several cardiovascular, respiratory and ocular conditions (for example aortic stenosis, hypotensive disorder, acute coronary syndrome, asthma, COPD, uveitis).
• Drug interactions (100 recorded; main examples):
  • Moderate: amphotericin B (including lipid complex, cholesteryl sulfate and liposomal forms), trospium, nitisinone.
  • Unknown severity: calcitriol, doxycycline, vancomycin, morphine, prednisone, proton pump inhibitors (omeprazole, pantoprazole, lansoprazole), famotidine, aspirin, and others.

Please refer to the TGA-approved Product Information (PI) for warnings and contraindications, as label-based safety data was not available.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---